Last 12 months
Inside the activity.
1 purchase rows · 3 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2023 Filed Apr 13, 2023 16:11 UTC |
Hata Yujiro SDirector · President and CEO
|
Exercise / conversionCommon Stock | 11,601 | $4.31 | $50,000.31 |
DisclosureSEC source: 0001610717-23-000007 · form4.xml · nonDerivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 677,887 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 17:01 UTC |
Stone Paul A.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001567619-23-003947 · doc1.xml · derivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 16:59 UTC |
Hata Yujiro SDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001567619-23-003944 · doc1.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 17:02 UTC |
Beaupre DarrinChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001567619-23-003948 · doc1.xml · derivative · entry 1 Beaupre Darrin · CIK 0001581198 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:04 UTC |
WHITE MICHAEL ANTHONYChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 165,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001567619-23-003950 · doc1.xml · derivative · entry 1 WHITE MICHAEL ANTHONY · CIK 0001890578 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 22:00 UTC |
Throne JasonChief Legal Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001567619-23-003945 · doc1.xml · derivative · entry 1 Throne Jason · CIK 0001790865 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:37 UTC |
YARNO WENDY LDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012703 · doc1.xml · derivative · entry 1 YARNO WENDY L · CIK 0001181186 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:22 UTC |
Stein JeffreyDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012696 · doc1.xml · derivative · entry 1 Stein Jeffrey · CIK 0001478831 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:32 UTC |
ROSEN TERRY JDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012700 · doc1.xml · derivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 18:35 UTC |
SHANNON TIMOTHY MDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012702 · doc1.xml · derivative · entry 1 SHANNON TIMOTHY M · CIK 0001207114 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:27 UTC |
Kelley Susan L.Director
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012699 · doc1.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:25 UTC |
Kelley Susan L.Director
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012698 · doc1.xml · derivative · entry 1 Kelley Susan L. · CIK 0001519612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:23 UTC |
Morrison Scott WDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012697 · doc1.xml · derivative · entry 1 Morrison Scott W · CIK 0001662426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 22:22 UTC |
Hampton Malcolm GarretDirector
|
GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012694 · doc1.xml · derivative · entry 1 Hampton Malcolm Garret · CIK 0001698265 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2032-06-08 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. Read SEC document |
| April 05, 2022 Filed Apr 6, 2022 20:23 UTC |
MACKEY CATHERINE JDirector
|
GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $11.80 | $0.00 |
DisclosureSEC source: 0001567619-22-008194 · doc1.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-04-04 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from April 5, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 19:46 UTC |
Stone Paul A.SVP, Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 92,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001567619-22-006126 · doc1.xml · derivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 19:44 UTC |
Hata Yujiro SDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 260,000 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001567619-22-006124 · doc1.xml · derivative · entry 1 Hata Yujiro S · CIK 0001649119 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Stock · 260,000 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:45 UTC |
WHITE MICHAEL ANTHONYSVP, Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 92,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001567619-22-006125 · doc1.xml · derivative · entry 1 WHITE MICHAEL ANTHONY · CIK 0001890578 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:40 UTC |
Throne JasonSVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 63,750 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001567619-22-006123 · doc1.xml · derivative · entry 1 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Underlying: Common Stock · 63,750 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 25, 2021 Filed Oct 27, 2021 21:16 UTC |
WHITE MICHAEL ANTHONYSVP, Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $22.01 | $0.00 |
DisclosureSEC source: 0001567619-21-018800 · doc1.xml · derivative · entry 1 WHITE MICHAEL ANTHONY · CIK 0001890578 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-10-24 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 25, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $11.08 | $0.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 1,500 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 1,000 | $26.62 | $26,621.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $26.42 to $26.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 500 | $25.85 | $12,924.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.39 to $26.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 7, 2021 20:11 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 1,500 | $11.08 | $16,620.00 |
DisclosureSEC source: 0001567619-21-018029 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,313 | $0.00 Strike: $11.08 | $0.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · derivative · entry 9 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,937 Underlying: Common Stock · 4,313 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 19, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,071 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · derivative · entry 8 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,048 Underlying: Common Stock · 7,071 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 200 | $27.67 | $5,534.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 6 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 11,184 | $27.41 | $306,559.03 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 5 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,989 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $26.56 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 4,313 | $11.08 | $47,788.04 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 7,071 | $4.31 | $30,476.01 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 17:41 UTC |
Stone Paul A.SVP, Chief Financial Officer
|
SaleCommon Stock | 2,500 | $27.42 | $68,542.50 |
DisclosureSEC source: 0001567619-21-016924 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,944 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $27.37 to $27.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 116 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · derivative · entry 7 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,119 Underlying: Common Stock · 116 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 116 | $27.46 | $3,185.00 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $27.45 to $27.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 23:24 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 116 | $4.31 | $499.96 |
DisclosureSEC source: 0001567619-21-016927 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 22:48 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 10,000 | $25.09 | $250,943.00 |
DisclosureSEC source: 0001567619-21-016820 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $24.95 to $25.25, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,235 Underlying: Common Stock · 1,500 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 400 | $23.52 | $9,406.00 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $23.49 to $23.55, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 11,100 | $22.96 | $254,862.66 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,189 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $22.48 to $23.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:19 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 1,500 | $4.31 | $6,465.00 |
DisclosureSEC source: 0001567619-21-015084 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · derivative · entry 5 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,735 Underlying: Common Stock · 5,000 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from February 27, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 Underlying: Common Stock · 5,000 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 10,000 | $25.15 | $251,460.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $24.95 to $25.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 5,000 | $4.31 | $21,550.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:18 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionCommon Stock | 5,000 | $6.92 | $34,600.00 |
DisclosureSEC source: 0001567619-21-014178 · doc1.xml · nonDerivative · entry 1 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:17 UTC |
Throne JasonSVP, General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.34 | $0.00 |
DisclosureSEC source: 0001567619-21-014176 · doc1.xml · derivative · entry 3 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,610 Underlying: Common Stock · 10,000 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:17 UTC |
Throne JasonSVP, General Counsel
|
SaleCommon Stock | 10,000 | $25.17 | $251,683.00 |
DisclosureSEC source: 0001567619-21-014176 · doc1.xml · nonDerivative · entry 2 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.00 to $25.26, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 27, 2021 Filed Jul 29, 2021 21:17 UTC |
Throne JasonSVP, General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $13.34 | $133,400.00 |
DisclosureSEC source: 0001567619-21-014176 · doc1.xml · nonDerivative · entry 1 Throne Jason · CIK 0001790865 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:01 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-21-013156 · doc1.xml · derivative · entry 4 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,500 Underlying: Common Stock · 1,500 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:01 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 100 | $22.76 | $2,276.00 |
DisclosureSEC source: 0001567619-21-013156 · doc1.xml · nonDerivative · entry 3 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,789 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 23:01 UTC |
Dillon Michael P.SVP, Chief Scientific Officer
|
SaleCommon Stock | 1,400 | $22.20 | $31,081.96 |
DisclosureSEC source: 0001567619-21-013156 · doc1.xml · nonDerivative · entry 2 Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,889 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.70 to $22.5450, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.